With the name of Saxenda (liraglutide [in recombinant DNA] in injection) the drug is approved for use in adults with a body mass index (BMI) of 30 or more (overweight) or with a BMI of 27 or more (Overweight) and having at least one weight-related condition, such as hypertension, type 2 diabetes or high cholesterol (dyslipidemia).
“The Saxenda, used responsibly in combination with a healthy lifestyle that includes exercise and a low-calorie diet, offers an alternative treatment option to control chronic overweight in obese, overweight and overweight people At least one comorbid weight-related condition, “said Dr. James Smith, MD, MS, acting deputy director of the Metabolic and Endocrinological Products Section of the FDA’s Drug Evaluation and Research Center.
Side effects include pancreatitis, gallbladder disease, kidney failure, and suicidal thoughts. At the same time it is not recommended for patients with thyroid cancer.
The FDA also conditioned the approval of the drug to a series of tests and tests that should be done once it starts to be marketed.